Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
16 July 2020Website:
http://www.relaytx.comNext earnings report:
08 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 28 Jun 2024 23:17:10 GMTDividend
Analysts recommendations
Institutional Ownership
RLAY Latest News
3 new programs include 2 genetic disease programs – vascular malformations & Fabry disease – & 1 precision oncology program – NRAS-specific inhibitor Cash guidance remains unchanged, and is expected to fund operations into second half of 2026 Relay Therapeutics to host webcast event today, June 6, at 8:00 a.m. ET CAMBRIDGE, Mass.
Relay Therapeutics, Inc. (RLAY) reported a quarterly loss of $0.62 per share, which was lower than the expected loss of $0.70 per share according to the Zacks Consensus Estimate. This is an improvement from the loss of $0.78 per share reported in the same quarter last year.
Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company, will be participating in three upcoming fireside chats, including the Stifel 2024 Virtual Targeted Oncology Forum on April 17, 2024 at 1:00 p.m.
The mean of analysts' price targets for Relay Therapeutics, Inc. (RLAY) points to a 146.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
The mean of analysts' price targets for Relay Therapeutics, Inc. (RLAY) points to a 131.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Relay Therapeutics, Inc. (RLAY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
We're still in the initial stages of a massively disruptive artificial intelligence ( AI ) boom. Big Tech is investing billions of dollars into it.
Relay Therapeutics has maintained clinical momentum in its Phase 1/2 ReFocus trial for RLY-4008, showing promise for FGFR2-altered cholangiocarcinoma. The company's financial health is strong, with ample short-term liquidity and significant assets covering debts. Market sentiment is skeptical, with high short interest and the stock's underperformance relative to the S&P 500, but prominent institutions show confidence in the company's long-term prospects.
CAMBRIDGE, Mass., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that data for RLY-4008 (lirafugratinib) in patients with advanced FGFR2-altered solid tumors outside of cholangiocarcinoma will be presented at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place October 11-15, 2023.
Relay Therapeutics, Inc. (RLAY) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to loss of $0.71 per share a year ago.
What type of business is Relay Therapeutics?
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
What sector is Relay Therapeutics in?
Relay Therapeutics is in the Healthcare sector
What industry is Relay Therapeutics in?
Relay Therapeutics is in the Biotechnology industry
What country is Relay Therapeutics from?
Relay Therapeutics is headquartered in United States
When did Relay Therapeutics go public?
Relay Therapeutics initial public offering (IPO) was on 16 July 2020
What is Relay Therapeutics website?
https://www.relaytx.com
Is Relay Therapeutics in the S&P 500?
No, Relay Therapeutics is not included in the S&P 500 index
Is Relay Therapeutics in the NASDAQ 100?
No, Relay Therapeutics is not included in the NASDAQ 100 index
Is Relay Therapeutics in the Dow Jones?
No, Relay Therapeutics is not included in the Dow Jones index
When does Relay Therapeutics report earnings?
The next expected earnings date for Relay Therapeutics is 08 August 2024